{"id":14302,"date":"2022-04-07T14:16:15","date_gmt":"2022-04-07T13:16:15","guid":{"rendered":"https:\/\/www.ulsguarda.min-saude.pt\/?p=14302"},"modified":"2022-04-07T14:27:23","modified_gmt":"2022-04-07T13:27:23","slug":"5-ensaios-clinicos-estudos-observacionais","status":"publish","type":"post","link":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/servicos\/suporte-prestacao\/gec\/5-ensaios-clinicos-estudos-observacionais\/","title":{"rendered":"5 | Ensaios Cl\u00ednicos\/Estudos Observacionais"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Promotor<\/strong><\/p>\n<\/td>\n

\n

Servi\u00e7o<\/strong><\/p>\n<\/td>\n

\n

Investigador Principal<\/strong><\/p>\n<\/td>\n

\n

Ensaio<\/strong><\/p>\n<\/td>\n<\/tr>\n

BAYER<\/td>\nMEDICINA INTERNA<\/td>\nDr\u00aa Maria Jo\u00e3o Baldo<\/td>\nFINEARTS <\/strong>– A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants.<\/td>\n<\/tr>\n
ABBVIE<\/td>\n\n

REUMATOLOGIA<\/p>\n

MEDICINA INTERNA<\/p>\n<\/td>\n

Dr\u00aa Cla\u00fadia Vaz<\/td>\nM16-852<\/strong> – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis.<\/td>\n<\/tr>\n
INSMED<\/td>\nPNEUMOLOGIA<\/td>\nDr\u00aa Alcina Tavares<\/td>\nASPEN –<\/strong> A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis.<\/td>\n<\/tr>\n
SANOFI<\/td>\nPNEUMOLOGIA<\/td>\nDr. Jos\u00e9 Manuel Silva<\/td>\nAERIFY –<\/strong> Randomized, doub le-blind, placebo-controlled, parallelgroup Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340\/REGN3500\/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).<\/td>\n<\/tr>\n
NOVO NORDISK<\/td>\nMEDICINA INTERNA<\/td>\nDr. Adriano Cardoso<\/td>\nESSENCE \u2013 <\/strong>The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis<\/td>\n<\/tr>\n
POLYPID<\/td>\nCIRURGIA<\/td>\nProf. Doutor Augusto Louren\u00e7o<\/td>\nD-PLEX \u2013<\/strong> Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two\u2010arm, Double Blind Study to Assess Efficacy and Safety of D\u2010PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.<\/td>\n<\/tr>\n
JANSSEN<\/td>\nUNIDADE ONCOLOGIA<\/td>\nDr\u00aa In\u00eas Sequeira<\/td>\nCAPA<\/strong> \u2013 Characterization of Castrate-Resistant Prostate Cancer patients followed in Urology Department of Portuguese hospitals.<\/td>\n<\/tr>\n
PFIZER<\/td>\nINFECIOLOGIA<\/td>\nDr\u00aa Catarina Quinaz<\/td>\nOZAVIE \u2013 <\/strong>A prospective, multicentre, observational study in hospitalized patients suffering from infections and treated with ZAVICEFTA\u00ae (ceftazidime\/avibactam) under actual conditions of use.<\/td>\n<\/tr>\n
GILEAD<\/td>\nUNIDADE ONCOLOGIA<\/td>\nDr\u00aa In\u00eas Sequeira<\/td>\nTROPICS \u2013<\/strong> A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician\u2019s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer.<\/td>\n<\/tr>\n
ASTRAZENECA<\/td>\nPNEUMOLOGIA<\/td>\nDr. Jos\u00e9 Manuel Silva<\/td>\nLOGOS <\/strong>\u2013 A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort\u00ae Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma.<\/td>\n<\/tr>\n
GSK<\/td>\nPNEUMOLOGIA<\/td>\nDr. Jos\u00e9 Manuel Silva<\/td>\nSWIFT \u2013<\/strong> A 52-week, andomized, double-blind, placebo-controlled, parallelgroup, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype.<\/td>\n<\/tr>\n
GSK<\/td>\nPNEUMOLOGIA<\/td>\nDr. Jos\u00e9 Manuel Silva<\/td>\nNIMBLE \u2013<\/strong> A 52-week, Randomized, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.<\/td>\n<\/tr>\n
SEAGEN<\/td>\nONCOLOGIA<\/td>\nDr\u00aa In\u00eas Sequeira<\/td>\nMOUNTAINER –<\/strong> An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzamab and mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer.<\/td>\n<\/tr>\n
NOVARTIS<\/td>\nREUMATOLOGIA<\/td>\nDr\u00aa Cl\u00e1udia Vaz<\/td>\nNEPTUNUS: <\/strong>A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sj\u00f6gren\u2019s syndrome.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Promotor Servi\u00e7o Investigador Principal Ensaio BAYER MEDICINA INTERNA Dr\u00aa Maria Jo\u00e3o Baldo FINEARTS – A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants. ABBVIE REUMATOLOGIA MEDICINA INTERNA Dr\u00aa Cla\u00fadia Vaz M16-852 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and […]<\/p>\n","protected":false},"author":45,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[185],"tags":[],"class_list":["post-14302","post","type-post","status-publish","format-standard","hentry","category-gec"],"_links":{"self":[{"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/posts\/14302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/users\/45"}],"replies":[{"embeddable":true,"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/comments?post=14302"}],"version-history":[{"count":4,"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/posts\/14302\/revisions"}],"predecessor-version":[{"id":14306,"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/posts\/14302\/revisions\/14306"}],"wp:attachment":[{"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/media?parent=14302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/categories?post=14302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/portaisuls-qua.azurewebsites.net\/ulsg\/wp-json\/wp\/v2\/tags?post=14302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}